

In the Claims:

Please amend the claims as shown below. Please add new claims 12-20.

1. (Currently amended) A compound of the formula 2-hydroxy-2-methyl-N-(4-X-3-(trifluoromethyl)phenyl)-3-(perfluoroacylamino)propionamide, where X is nitro, cyano or halo of atomic number 9-35 9-35, and perfluoroacylamido is from ~~2-3~~ 2-3 carbon atoms and of from ~~0-1~~ 0-1 hydrogen atom.
2. (Original) A compound according to Claim 1 of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoroacetylaminopropionamide).
3. (Original) A compound according to Claim 1 of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoropropionylaminopropionamide).
4. (Original) A method for treating symptoms of at least one of androgenic effluvium and alopecia in a host, said method comprising:
topically administering to said host a therapeutically effective amount for the treatment of said androgenic effluvium or alopecia of a composition comprising a compound according to Claim 1,
for a time sufficient to treat said androgenic effluvium or alopecia.
5. (Original) A method according to Claim 4, wherein said topically administering further comprises treatment with a second antiandrogenic agent for the treatment of androgenic effluvium or alopecia.
6. (Currently amended) The method according to Claim 4, wherein said therapeutically effective amount is at a daily dosage in the range of about ~~10-200mg/day~~ 10-200 mg/day.
7. (Original) A method of treating symptoms of a cutaneous affliction dependent upon the suppression or elimination of androgen receptor in a host, said method comprising:

topically administering to said host in a predetermined regimen an effective amount of a composition comprising a compound according to Claim 1 to treat said cutaneous affliction.

8. (Original) The method according to Claim 7, wherein said cutaneous affliction is a hyperandrogenic skin syndrome.

9. (Original) A cosmetic or pharmaceutical formulation comprising a compound according to Claim 1 in an amount of at least about 0.1% and a pharmacologically and/or cosmetically acceptable carrier.

10. (Original) A method for decreasing synthesis of cutaneous androgen receptors in a cell, said method comprising:

contacting said cell comprising said cutaneous androgen receptors with a compound according to Claim 1 in an amount sufficient to decrease synthesis of said cutaneous androgen receptors.

11. (Original) The method according to Claim 10, wherein said cell is a follicle cell.

Please add the following new claims.

12. (New) The method of Claim 4, wherein said method comprises:

topically administering to said host a therapeutically effective amount for the treatment of said androgenic effluvium or alopecia of a composition comprising a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoroacetyl amino)propionamide) sufficient to treat said androgenic effluvium or alopecia.

13. (New) The method of Claim 4, wherein said method comprises

topically administering to said host a therapeutically effective amount for the treatment of said androgenic effluvium or alopecia of a composition comprising a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoropropionyl amino)propionamide sufficient to treat said androgenic effluvium or alopecia.

14. (New) The method of Claim 7, wherein said method comprises:
topically administering to said host in a predetermined regimen an effective amount of a composition comprising a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoroacetylamino)propionamide) to treat said cutaneous affliction.
15. (New) The method of Claim 7, wherein said method comprises:
topically administering to said host in a predetermined regimen an effective amount of a composition comprising a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoropropionylamino)propionamide to treat said cutaneous affliction.
16. (New) The method of Claim 10, said method further comprising:
contacting said cell comprising said cutaneous androgen receptors with a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoroacetylamino)propionamide) in an amount sufficient to decrease synthesis of said cutaneous androgen receptors.
17. (New) The method of Claim 10, said method further comprising:
contacting said cell comprising said cutaneous androgen receptors with a compound of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoropropionylamino)propionamide in an amount sufficient to decrease synthesis of said cutaneous androgen receptors.
18. (New) The method according to Claim 4, wherein said therapeutically effective amount is at a daily dosage in the range of about 0.1 mg to about 5g per day.
19. (New) The method of Claim 4, further comprising administering an extract of *Polygonum cuspidatum*.
20. (New) The method of Claim 19, wherein said extract comprises at least one of resveratrol and a glycon of resveratrol.